Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 23-34

  Chen, Jun ^a   Meng, Haoyu ^a   Xu, Lei ^a   Liu, Jie ^a,e   Kong, Deyu ^a   Chen, Pengsheng ^a   Gong, Xiaoxuan ^a   Bai, Jianling ^b   Zou, Fengwei ^c   Yang, Zhijian ^a   Li, Chunjian ^a   Eikelboom, John W ^d  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cilostazol; Dual antiplatelet therapy; Stent implantation; Triple antiplatelet therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; TETRAZOLE DERIVATIVE; TICLOPIDINE;

ANALOGS AND DERIVATIVES; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HEART INFARCTION; HUMAN; MALE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT; THROMBOSIS;

ASPIRIN; BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; STROKE; TETRAZOLES; THROMBOSIS; TICLOPIDINE;

EID: 84937760828     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1090-5     Document Type: Article

References (46)

1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241
2. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW et al (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113
3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678
4. Smit JJ, van’t Hof AW, de Boer MJ, Hoorntje JC, Dambrink JH et al (2006) Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 96:190–195
5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130
6. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533
7. Reaume KT, Regal RE, Dorsch MP (2008) Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother 42:550–557
8. Goto S (2005) Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 6:3–11
9. Cone J, Wang S, Tandon N, Fong M, Sun B et al (1999) Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 34:497–504
10. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S et al (2009) Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 68:4–13
11. Min PK, Jung JH, Ko YG, Choi D, Jang Y et al (2007) Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 71:1685–1690
12. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2007) Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 100:1103–1108
13. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2008) Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 51:1181–1187
14. Gao W, Zhang Q, Ge H, Guo Y, Zhou Z (2013) Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology 64:554–558
15. Youn YJ, Lee JW, Ahn SG, Lee SH, Choi H et al (2014) Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J 167:241–248
16. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E et al (2005) Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826–2832
17. Chen YD, Lu YL, Jin ZN, Yuan F, Lu SZ (2006) A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl) 119:360–366
18. Lee BK, Lee SW, Park SW, Lee SW, Park DW et al (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610–614
19. Kim JY, Lee K, Shin M, Ahn M, Choe H et al (2007) Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 71:1867–1872
20. Lu YL, Chen YD, Lu SZ (2007) Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 35:793–796 [in Chinese]
21. Kum DS, Kim MH, Paik JH, Yu LH, Han J et al (2009) Clinical effects of additional cilostazol administration after drug-eluting stent insertion. Korean Circ J 39:21–25
22. Han Y, Li Y, Wang S, Jing Q, Wang Z et al (2009) Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 157:733–739
23. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ et al (2010) Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 3:17–26
24. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH et al (2010) Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG trials). Am J Cardiol 105:168–173
25. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS (2011) Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 26:502–510
26. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al (2011) A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 57:1264–1270
27. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ et al (2011) Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 57:280–289
28. Lu YL, Pan WQ, Chen DY (2010) Cilostazol improves long-term clinical outcome after stenting in coronary heart disease patients. Chin J Geriatr Heart Brain Vessel Dis 12:690–692 [in Chinese]
29. Han YL, Su QF, Li Y, Kang J, Yan CH et al (2006) The effects of post coronary stenting triple antiplatelet therapies on platelet functions. Chin J Intern Med 45:635–638 [in Chinese]
30. Wang SL, Han YL, Jing QM, Wang ZL, Wang DM et al (2005) Long-term effects of cilostazol on clinical outcomes after coronary stent implantation in small-vessel lesions. J Fourth Mil Med Univ 26:994–997 [in Chinese]
31. Wang SL, Sun F, Zhao X, Chen LL, Feng GB et al (2010) Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 38:870–874 [in Chinese]
32. Lu YL, Chen YD, Lv SZ, Pan WQ, Liu X (2006) Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation. Chin J Geriatr 25:537–538 [in Chinese]
33. Kivela A, Hartikainen J (2006) Restenosis related to percutaneous coronary intervention has been solved? Ann Med 38:173–187
34. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD (2012) Role of endothelial shear stress in stent restenosis and thrombosis pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol 59:1337–1349
35. Morishita R (2005) A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl 6:41–46
36. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y et al (2004) Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44:1408–1414
37. Rogers KC, Faircloth JM, Finks SW (2012) Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother 46:839–850
38. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109
39. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention the GRAVITAS randomized trial. JAMA 305:1087–1095
40. Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN et al (2012) Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention the GIFT (genotype information and functional testing) study. J Am Coll Cardiol 59:1928–1937
41. Lee SW, Park SW, Yun SC, Kim YH, Park DW et al (2010) Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-eluting stenting followed by cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 159:284–291
42. Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R (2013) Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 167:2250–2258
43. Wang P, Zhou SJ, Zhou R, Liu G, Tang P et al (2012) The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. Clin Cardiol 35:598–604
44. Geng DF, Liu M, Jin DM, Wu W, Deng J et al (2012) Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology 122:148–157
45. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK et al (2012) A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 122:133–143
46. Friedland SN, Eisenberg MJ, Shimony A (2012) Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 109:1397–1404